We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Aerobic Bacteria Rapidly Identified by MALDI-TOF Mass Spectrometry

By LabMedica International staff writers
Posted on 27 Jan 2016
Print article
Image: The Microflex LT bench-top MALDI-TOF mass spectrometer and BioTyper (Photo courtesy of Bruker Daltonics).
Image: The Microflex LT bench-top MALDI-TOF mass spectrometer and BioTyper (Photo courtesy of Bruker Daltonics).
Image: Schematics of the Bruker MALDI BioTyper Workflow (Photo courtesy of Professor Melissa B. Miller).
Image: Schematics of the Bruker MALDI BioTyper Workflow (Photo courtesy of Professor Melissa B. Miller).
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a diagnostic tool for the identification of organisms routinely found in the microbiology laboratory.

MALDI-TOF MS has been proven to be a rapid and cost-effective diagnostic method for routine use in the clinical microbiology laboratory and MALDI-TOF MS technology uses ionizing laser for structural elements of the isolate to generate isolate-derived spectra, which is then compared to a reference database.

Scientists at the Children's Hospital Los Angeles (CA, USA) and their colleague at the Keck School of Medicine (Los Angeles, CA, USA) used isolates previously recovered by routine culture and workup from clinical specimens were cultured to appropriate media, identified directly by MALDI-TOF MS, and compared to results from various biochemical identification methods. A total of 996 aerobic Gram-positive and Gram-negative organism isolates were included in the study.

All MALDI-TOF MS testing was performed in duplicate with the same swab spotted onto two spots on the target plate, one spot representing a “heavy” inoculum and the second spot representing a “light” inoculum. Acquisition and analysis of mass spectra was performed using the Microflex LT mass spectrometer (Bruker Daltonics; Fremont, CA, USA). For media studies, 84 Gram-negative bacteria were cultured on blood agar, chocolate agar, and MacConkey agar; 74 Gram-positive bacteria were cultured on blood agar, chocolate agar, and colistin nalidixic acid (CNA) agar. For temperature and stability studies, four Gram-negative bacteria and four Gram-positive bacteria were cultured onto blood agar. Results of MALDI-TOF MS were compared to routine methods performed in the microbiology laboratory. All discordant identifications were confirmed by additional biochemical or 16S rRNA sequencing.

In MALDI-TOF MS data interpretation, a score of equal to or greater than 2.0 is equivocal to reliable species-level identification, a score of 1.7–1.99 is considered reliable to the genus level and a score of less than 1.7 is considered unreliable for bacteria identification. Using the direct-smear method, 99.5% and 98.0% of aerobic Gram-negative and Gram-positive bacteria, respectively, were identified to the genus level. At a score of equal to or greater than 1.9, 97.6% Gram-negative organisms and 94.6% Gram-positive organisms were correctly identified to the species level by direct-smear method. Only 1.1% of isolates required further reflex to direct-plate extraction. The direct-smear method proved to be robust, as various growth temperatures, media, culture age, and different operators had no notable impact on the bacterial identification rate.

The authors concluded that the direct-smear method was accurate and effective in streamlining the workflow of Gram-positive and Gram-negative bacterial identification in our clinical laboratory. For simplicity, they recommend using the direct-smear method for the majority of specimens commonly found in the clinical laboratory and an optimized spectral score cutoff of equal to or greater than 1.9 for enhanced species-level identification rates. The study was first published on December 14, 2015, in the Journal of Clinical Laboratory Analysis.

Related Links:

Children's Hospital Los Angeles 
Keck School of Medicine 
Bruker Daltonics 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.